Jeffrey Eisele - Jan 12, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Development Officer
Signature: /s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol: APLS
Transactions as of: Jan 12, 2023
Transactions value $: $1,867,956
Form type: 4
Date filed: 1/17/2023, 06:35 PM
Previous filing: Dec 23, 2022
Next filing: Jan 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+22.6K	+71.34%	$0.00	54.2K	Jan 12, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$1.87M	+35.5K		$52.66	35.5K	Jan 12, 2023	Common Stock	35.5K	$52.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F2	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.